Bailey G. Fitzgerald

Roswell Park Comprehensive Cancer Center — United States

Medicine · Health Sciences

6h-index235citations37works7.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Occupational and environmental lung diseases(17), Pleural and Pulmonary Diseases(13), Medical Imaging and Pathology Studies(13), Cancer Immunotherapy and Biomarkers(6), Lung Cancer Treatments and Mutations(6)

Publications37 total

Long-term follow up of nivolumab/ipilimumab-primed immunotransplant in patients with Relapsed/Refractory DLBCL
Blood·2025Open Access
Radiotherapy for Unresectable Locally Advanced NSCLC: A Practical Multidisciplinary Approach to Challenging Scenarios From the International Association for the Study of Lung Cancer Advanced Radiation Technology Subcommittee
Journal of Thoracic Oncology·2025
Glucagon-like peptide-1 receptor agonism improves lung cancer outcomes and tumor growth control
JCI Insight·2025Open Access
Prediction of checkpoint inhibitor immunotherapy efficacy for cancer using routine blood tests and clinical data
Nature Medicine·2025· 79 citedOpen Access
Supplementary Figure S1 from Single-Cell View of Tumor Microenvironment Gradients in Pleural Mesothelioma
2024Open Access
Supplementary Table S5 from Single-Cell View of Tumor Microenvironment Gradients in Pleural Mesothelioma
2024Open Access
Data from Single-Cell View of Tumor Microenvironment Gradients in Pleural Mesothelioma
2024Open Access
Supplementary Figure S6 from Single-Cell View of Tumor Microenvironment Gradients in Pleural Mesothelioma
2024Open Access
Supplementary Table S1 from Single-Cell View of Tumor Microenvironment Gradients in Pleural Mesothelioma
2024Open Access
Supplementary Figure S5 from Single-Cell View of Tumor Microenvironment Gradients in Pleural Mesothelioma
2024Open Access
Supplementary Table S3 from Single-Cell View of Tumor Microenvironment Gradients in Pleural Mesothelioma
2024Open Access
Supplementary Figure S2 from Single-Cell View of Tumor Microenvironment Gradients in Pleural Mesothelioma
2024Open Access
Supplementary Figure S3 from Single-Cell View of Tumor Microenvironment Gradients in Pleural Mesothelioma
2024Open Access
Supplementary Table S2 from Single-Cell View of Tumor Microenvironment Gradients in Pleural Mesothelioma
2024Open Access
Supplementary Table S4 from Single-Cell View of Tumor Microenvironment Gradients in Pleural Mesothelioma
2024Open Access
Supplementary Figure S4 from Single-Cell View of Tumor Microenvironment Gradients in Pleural Mesothelioma
2024Open Access
Supplementary Table S6 from Single-Cell View of Tumor Microenvironment Gradients in Pleural Mesothelioma
2024Open Access
Consolidation ALK Tyrosine Kinase Inhibitors Versus Durvalumab or Observation After Chemoradiation in Unresectable Stage III ALK-Positive NSCLC
Journal of Thoracic Oncology·2024· 9 citedOpen Access
Single-Cell View of Tumor Microenvironment Gradients in Pleural Mesothelioma
Cancer Discovery·2024· 22 cited
Global retrospective study comparing consolidation ALK tyrosine kinase inhibitors (TKI) to durvalumab (durva) or observation (obs) after chemoradiation (CRT) in unresectable locally-advanced ALK+ non-small cell lung cancer (NSCLC).
Journal of Clinical Oncology·2024· 5 cited
page 1 of 2Next →

Frequent Co-authors

Thomas U. Marron(25), Miriam Mérad(19), Sacha Gnjatic(18), Samarth Hegde(17), Robert E. Sweeney(16), Seunghee Kim‐Schulze(16), Raja M. Flores(16), Andrea Wolf(16), Alexander M. Tsankov(16), Bruno Giotti(15), Komal Dolasia(15), William Zhao(15), Peiwen Cai(15), Elliot Merritt(15), Evgeny Kiner(15), Grace Kim(15), Atharva Bhagwat(15), Sanjana Shroff(15), Travis Dawson(15), Jamshid Abdul‐Ghafar(15)